Black checkmark with a sparkle and a curved line underneath on a white background.
Company

TuHURA Biosciences, Inc./NV

Ticker
HURA
Sector
Industry
Report date
November 13, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent developments highlight TuHURA's clinical progress, regulatory milestones, and analyst coverage.

Recent developments:
  • TuHURA reported early clinical responses in a deep-seated Merkel Cell Cancer study as of October 26, 2026.[N1]
  • The company received FDA IND clearance for TBS-2025 in acute myeloid leukemia on September 14, 2026.[N2]
  • TuHURA highlighted Phase III development plans for IFx-2.0 and AML trial plans at a Canaccord event on August 14, 2026.[N3]
  • Citizens initiated coverage of TuHURA Biosciences with a market outperform recommendation on April 28, 2026.[N4]
  • TuHURA received orphan drug status for IFx-2.0 in Stage IIB-IV cutaneous melanoma as of February 2, 2026.[N6][N7]
  • The company entered a definitive merger agreement to acquire Kineta in December 2024.[N4]
Overview

TuHURA Biosciences operates as a clinical-stage biopharmaceutical company developing novel therapies primarily for cancer indications. Its lead candidates include IFx-2.0, targeting metastatic Merkel Cell Carcinoma and cutaneous melanoma, and TBS-2025 for acute myeloid leukemia. The company has received regulatory milestones such as orphan drug designation and FDA IND clearance for its pipeline. TuHURA also completed a merger agreement to acquire Kineta, expanding its development portfolio. The company is currently in clinical trial phases with ongoing research and development activities.

Executive summary

TuHURA Biosciences, Inc./NV is a clinical-stage biopharmaceutical company focused on oncology drug development. The company has active clinical programs including a Phase 3 trial for IFx-2.0 in metastatic Merkel Cell Carcinoma and an IND-cleared program for TBS-2025 in AML. TuHURA received orphan drug designation for IFx-2.0 in cutaneous melanoma. Financially, as of September 30, 2026, the company reported cash and equivalents of $1.89 million, current liabilities exceeding current assets with a current ratio of 0.47, and a net loss of $6.41 million for the nine months ended. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for HURA

Bull case model:

TuHURA has advanced clinical programs with regulatory designations such as orphan drug status for IFx-2.0 and FDA IND clearance for TBS-2025, indicating progress in its pipeline. Early clinical responses in Merkel Cell Cancer studies and planned Phase III trials demonstrate active development. The acquisition of Kineta may broaden its pipeline and capabilities. Positive analyst coverage and market interest reflect recognition of its potential in oncology therapeutics.

Bear case model:

TuHURA faces significant risks typical of clinical-stage biopharmaceutical companies, including regulatory uncertainties, clinical trial risks, and financial constraints. The company reported a net loss and has a current ratio below 1, indicating liquidity challenges. Success depends on continued funding, regulatory approvals, and clinical trial outcomes, which are inherently uncertain. Failure in any of these areas could materially impact the company’s prospects.

Moat:

TuHURA's moat is based on its proprietary drug candidates in oncology with orphan drug designations and FDA regulatory clearances that provide certain exclusivities and development advantages. The company’s clinical-stage assets and ongoing trials represent specialized knowledge and intellectual property that could create barriers to entry. However, as a clinical-stage company without commercial products, its moat is contingent on successful clinical development and regulatory approvals.

Risks overview
Risks summary
The biggest risk for TuHURA Biosciences is the uncertainty inherent in clinical development and regulatory approval processes combined with financial and liquidity constraints that may impact its ability to sustain operations and advance its drug candidates.
Risks details:

• Regulatory Approval Risk: The company’s drug candidates require FDA and other regulatory approvals, which are lengthy, time-consuming, and unpredictable. Delays or failures in obtaining approvals could impair commercialization prospects.[S1][S2]
• Financial and Liquidity Risk: As of September 30, 2026, TuHURA had a current ratio of 0.47 and a cash ratio of 0.24, indicating potential liquidity constraints. The company reported net losses and depends on raising funds for ongoing operations and clinical development.[S2]
• Clinical Development Risk: Clinical trials may not demonstrate safety or efficacy required for approval. Partial clinical holds and trial delays can impact timelines and costs.[N1][S2]
• Operational and Execution Risk: The company’s ability to recruit and retain qualified personnel and manage development programs effectively is critical. Integration of acquired assets such as Kineta presents execution challenges.[S1]

FINAL FORECAST FOR HURA

Final take one line
TuHURA Biosciences is a clinical-stage biopharmaceutical company with active oncology drug development programs, regulatory milestones, and financial challenges typical of its stage.
Final take 12 to 24 month view

Business trends: Progress in clinical trials for IFx-2.0 and TBS-2025 with regulatory designations and early clinical responses.
Execution milestones: Advancement of Phase III trials, FDA IND clearances, orphan drug designations, and integration of Kineta acquisition.
Key risks: Regulatory approval uncertainties, clinical trial risks, financial and liquidity constraints, and operational execution challenges.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • TuHURA Biosciences, Inc./NV is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other diseases.
  • The company has multiple drug candidates in development, including IFx-2.0 and TBS-2025.
  • IFx-2.0 has received FDA orphan drug designation for treatment of Stage IIB to Stage IV cutaneous melanoma as of February 2, 2026.[N6][N7]
  • TuHURA has an ongoing Phase 3 clinical trial for IFx-2.0 targeting metastatic Merkel Cell Carcinoma (MCC), with the FDA lifting a partial clinical hold previously placed on this trial.[N1][S2]
  • The company received FDA IND clearance for TBS-2025 in acute myeloid leukemia (AML) as of September 14, 2026.[N2]
  • TuHURA has highlighted plans for Phase III development of IFx-2.0 and AML trial plans for TBS-2025 as of August 14, 2026.[N3]
  • TuHURA entered a definitive merger agreement to acquire Kineta, a company with complementary assets, as of December 12, 2024.[N4]
  • The company reported early clinical responses in a deep-seated Merkel Cell Cancer study as of October 26, 2026.[N1]
  • TuHURA has been covered by multiple analysts with buy or market outperform recommendations.[N4]
  • As of September 30, 2026, TuHURA had cash and cash equivalents of approximately $1.89 million and current assets of about $3.68 million, with current liabilities of approximately $7.76 million, resulting in a current ratio of 0.47 and a cash ratio of 0.24.[S2]
  • The company reported a net loss of approximately $6.41 million for the nine months ended September 30, 2026, with basic and diluted EPS of -$0.10 per share.[S2]
  • TuHURA is a smaller reporting company and is not a shell company as of November 10, 2026, with approximately 65.8 million shares outstanding.[S2]
  • The company’s business involves significant regulatory and clinical development risks, including the unpredictability of FDA approvals and the need to raise funds for ongoing operations.[S1][S2]
Sources
Sources - Context summary

Generated 2026-11-13

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-04-30 | 10-K/A
  • S2 | 2026-11-13 | 10-Q
Sources - News headlines
  • N1 | 2026-10-26 | www.nasdaq.com | TuHURA Reports Early Responses in Deep-Seated Merkel Cell Cancer Study | https://www.nasdaq.com/articles/tuhura-reports-early-responses-deep-seated-merkel-cell-cancer-study
  • N2 | 2026-09-14 | www.nasdaq.com | TuHURA Biosciences Receives FDA IND Clearance For TBS-2025 In AML | https://www.nasdaq.com/articles/tuhura-biosciences-receives-fda-ind-clearance-tbs-2025-aml
  • N3 | 2026-08-14 | www.nasdaq.com | TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord | https://www.nasdaq.com/articles/tuhura-biosciences-highlights-phase-iii-ifx-push-aml-trial-plans-canaccord
  • N4 | 2026-04-28 | www.nasdaq.com | Citizens Initiates Coverage of TuHURA Biosciences (HURA) with Market Outperform Recommendation | https://www.nasdaq.com/articles/citizens-initiates-coverage-tuhura-biosciences-hura-market-outperform-recommendation
  • N5 | 2026-04-02 | www.nasdaq.com | HURA, SVR, HUC: 3 Commodity ETFs to Hedge against Inflation | https://www.nasdaq.com/articles/hura-svr-huc-3-commodity-etfs-hedge-against-inflation
  • N6 | 2026-02-02 | www.nasdaq.com | TuHURA Gets Orphan Drug Status For IFx-2.0 In Stage IIB-IV Cutaneous Melanoma | https://www.nasdaq.com/articles/tuhura-gets-orphan-drug-status-ifx-20-stage-iib-iv-cutaneous-melanoma
  • N7 | 2026-02-02 | www.prnewswire.com | TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma | https://prnewswire.com/news-releases/tuhura-biosciences-received-fda-orphan-drug-designation-for-ifx-2-0-for-the-treatment-of-stage-iib-to-stage-iv-cutaneous-melanoma-302675770.html
  • N8 | 2025-12-10 | www.nasdaq.com | After-Hours Rally: Stoke Therapeutics, Alpha Tau Medical, Compass Pathways Lead Biotech Movers | https://www.nasdaq.com/articles/after-hours-rally-stoke-therapeutics-alpha-tau-medical-compass-pathways-lead-biotech
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine